Olympus Scope Lawsuit Update: Mid-June 2026 — Approaching the Import Alert Anniversary

June 24, 2026 marks one year since the U.S. Food and Drug Administration issued the import alert that blocked 58 Olympus device models from entering the United States. A year later, the alert is still in place. The FDA has not announced verification of Olympus's claimed corrective work. Three new 2026 recalls have widened the compliance picture rather than narrowed it. Individual lawsuits continue to be filed in state and federal courts. And there is still no MDL.

Why the Anniversary Matters

Import alerts are not permanent by design. They are administrative tools the FDA uses to block products from entering the United States until the underlying quality system violations are resolved. Most import alerts of this scale — covering 58 device models from a single facility — are resolved within months once a manufacturer demonstrates corrective action.

The Aizu, Japan import alert has now been in place for a full year. Olympus disclosed in its most recent investor materials that it had completed roughly 96% of the corrective actions tied to the FDA's quality system findings. The FDA has not independently verified that figure, has not lifted the alert, and has not publicly announced a timetable.

For patients and families with potential cases, the persistence of the alert matters in two ways. First, the alert is a formal regulatory finding that documents quality system violations — the kind of record that becomes evidence in product liability cases. Second, the fact that the FDA has not lifted it, despite Olympus's claimed near-completion, suggests the agency is not yet satisfied with the corrective work.

The 2026 Recall Pattern in Retrospect

Looking at 2026 in retrospect, the import alert is no longer an isolated event. Three additional Olympus recalls have entered the FDA database in the past six months:

• January 16, 2026 — High Flow Insufflation Units. A Class I recall covering the UHI, UHI-2, and UHI-3 insufflation units. The FDA ultimately tied this recall to 10 injuries and one death. Because no software correction was available, Olympus removed the products from the market entirely.
• January 22, 2026 — Endoscope needle recall expansion. An expansion of an earlier recall covering disposable endoscope needles produced at the same Aizu facility.
• April 8, 2026 — OER-Pro automated endoscope reprocessor recall. 3,354 units of the cleaning device hospitals use to reprocess Olympus duodenoscopes between patients, recalled due to MAJ-1443 and MAJ-1444 component incompatibilities. We covered this in our June 2026 litigation status update.

Three recalls in six months, across three different product categories (insufflation, disposable accessories, reprocessing equipment), is not the pattern of a manufacturer whose compliance work is winding down. It is the pattern of a manufacturer whose quality system problems continue to surface.

U.S. Litigation: Still Individual, Still No MDL

The structural picture in U.S. federal court is unchanged from our April, May, and early June updates. The Judicial Panel on Multidistrict Litigation has not consolidated Olympus duodenoscope cases. The spring 2026 JPML hearing sessions did not take up the question. The summer JPML session is the next natural opportunity, but no public docket entry suggests a centralization motion has been filed.

Plaintiffs continue to file individual product liability actions in state and federal courts across the country. Each case proceeds at the pace of its own court. There is no consolidated discovery, no MDL bellwether schedule, and no national settlement framework on the table.

What that means for prospective plaintiffs is the same thing we've said every month this year: your filing window is set by your state's statute of limitations, and that clock does not pause while everyone waits to see whether an MDL forms.

What to Do as Summer 2026 Approaches

Summer is a particularly relevant time of year to revisit a possible scope infection case. A few specific reasons:

• Spring colonoscopy season is winding down. Patients who had procedures in March, April, and May 2026 are now in the post-procedure window where infection symptoms typically present. Our scope infection symptom timeline guide walks through what to watch for.
• Statute of limitations dates are approaching for many earlier-injury patients. Patients hurt by Olympus scopes in 2024 may be running up against two- or three-year state filing deadlines this summer.
• The import alert may yet lift. If the FDA verifies Olympus's corrective work and lifts the alert in the second half of 2026, the regulatory pressure on the company changes, and so do settlement dynamics. Cases filed before any such shift are positioned to benefit from the current record.
• Hospital records have not yet aged out. Most hospitals retain procedure-level records and reprocessing logs for the time period of the 2024-2025 cases. Records requests filed now still produce complete files.

What to Watch the Rest of June

• The June 24 anniversary. Watch for any FDA announcement on or near that date regarding the Aizu facility status.
• Olympus quarterly earnings disclosures. The company's June-period investor disclosures typically include updates on regulatory progress and contingent liabilities related to the litigation.
• Any new field safety notices. The pattern of 2026 recalls suggests the next one is more likely than not within a few months.
• The Quebec class action. Documents produced in the April 2026 Siskinds LLP Quebec filing may eventually surface in U.S. discovery channels.

If You Were Affected

We represent patients nationwide, regardless of where the procedure happened. A free case review takes about 15 minutes by phone. We evaluate the medical timeline, the device involved, and your state's filing deadlines before you decide whether to move forward.

• See if your situation fits the case profile with our 3-part qualification test.
• Learn how to identify which scope was used in your procedure: Did Your Hospital Use Olympus Scopes?
• Review the superbug infection symptoms guide for warning signs to watch for.
• Read the regulatory backdrop: What the June 2025 FDA Import Alert Means for You.
• Read the prior cadence post: June 4, 2026 — When the Cleaning Equipment Itself Gets Recalled.

Free case review. No Fees Unless We Recover Money for You.

Sources

• U.S. Food & Drug Administration — "Import Alerts for Certain Olympus Medical Devices Manufactured in Japan: Letter to Health Care Providers" (June 24, 2025). fda.gov
• Olympus Corporation — Investor disclosures on quality-commitment progress and import-alert status. olympus-global.com/ir
• U.S. Food & Drug Administration — "Insufflation Unit Recall: Olympus Removes High Flow Insufflation Units" (January 2026, Class I). fda.gov
• FierceBiotech — "FDA links Olympus laparoscopic insufflation hardware recall to 10 injuries, one death." fiercebiotech.com
• American Hospital Association — "Olympus expands recall of endoscope needles" (January 22, 2026). aha.org
• U.S. FDA Medical Device Recalls Database — Olympus OER-Pro automated endoscope reprocessor (April 8, 2026; 3,354 units). fda.gov
• Judicial Panel on Multidistrict Litigation — Pending MDL list and hearing sessions. jpml.uscourts.gov
• U.S. FDA MAUDE Adverse Event Database — Olympus duodenoscope reports. accessdata.fda.gov